methyl (E)-4-cyano-3-methylbut-3-enoate | 102928-68-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: methyl (E)-4-cyano-3-methylbut-3-enoate
• 英文别名: methyl 4-Cyano-3-methylbut-3-enoate；methyl 3-(cyanomethylene)butyrate；(E)-methyl 4-cyano-3-methylbut-3-enoate
• CAS: 102928-68-7
• 化学式: C₇H₉NO₂
• 分子量: 139.154
• InChiKey: AQIIMPXBVSEJQA-ZZXKWVIFSA-N

物化性质

• 沸点：
  243.1±23.0 °C(Predicted)
• 密度：
  1.035±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  50.1
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  methyl (E)-4-cyano-3-methylbut-3-enoate 在 氢氧化钾 、 potassium tert-butylate 作用下， 以 甲醇 为溶剂， 反应 20.0h， 生成 (2E,4Z,6E,8E)-4-cyano-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoic acid
  参考文献：
  名称：

  亚甲基或末端侧链修饰的类视黄醇对NB4早幼粒细胞白血病细胞分化和细胞死亡信号转导的结构活性关系。

  摘要：

  研究了一系列的亚甲基或侧链修饰的类维生素A在NB4急性早幼粒细胞白血病细胞上的新的结构-活性关系。基于它们的选择性视黄酸受体结合特性，分析了这些化合物的诱导分化和凋亡的潜力。

  DOI：

  10.1016/j.bmcl.2004.06.002
• 作为产物：
  描述：

  3-氧丁酸 、 氰乙酸 在 ammonium acetate 作用下， 以 溶剂黄146 、 苯 为溶剂， 反应 24.0h， 生成 (Z)-methyl 4-cyano-3-methylbut-3-enoate 、 methyl (E)-4-cyano-3-methylbut-3-enoate
  参考文献：
  名称：

  Methods for inhibiting protein kinases

  摘要：

  本发明提供了利用咪唑并[1,2-a]吡嗪化合物抑制来自AKT、检查点激酶、枢纽激酶、Pim-1激酶和酪氨酸激酶的蛋白激酶的方法，以及利用这些化合物治疗、预防、抑制或改善与蛋白激酶相关的一种或多种疾病的方法。

  公开号：

  US20070105864A1

文献信息

• Imidazopyrazines as protein kinase inhibitors
  申请人：Zhao Lianyun

  公开号：US20070117804A1

  公开（公告）日：2007-05-24

  In its many embodiments, the present invention provides a novel class of imidazopyrazine compounds as inhibitors of protein and/or checkpoint kinases, methods of preparing such compounds, pharmaceutical compositions including one or more such compounds, methods of preparing pharmaceutical formulations including one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the protein or checkpoint kinases using such compounds or pharmaceutical compositions.

  本发明的多种实施例提供了一类新型的咪唑吡嗪化合物，作为蛋白质和/或检查点激酶的抑制剂，包括制备这类化合物的方法、包含一个或多个这类化合物的药物组合物、制备包含一个或多个这类化合物的药物制剂的方法，以及使用这类化合物或药物组合物治疗、预防、抑制或改善与蛋白质或检查点激酶相关的一个或多个疾病的方法。
• Nitrogen-containing heterocyclic ring derivatives and analgesic and
  申请人：Yamanouchi Pharmaceutical Co., Ltd.

  公开号：US04288438A1

  公开（公告）日：1981-09-08

  Novel nitrogen-containing heterocyclic compounds shown by the formula ##STR1## wherein one of R.sub.1 and R.sub.2 represents a lower alkyl group, a phenyl group, a halophenyl group, or a lower alkoxyphenyl group and the other of them represents a hydrogen atom, a lower alkyl group, or a phenyl lower alkyl group; said R.sub.1 and R.sub.2 may combine with each other to form a trimethylene group or a tetramethylene group; R.sub.3 represents a hydrogen atom, a lower alkyl group, a phenyl group, or a phenyl lower alkyl group; X represents an oxygen atom, a sulfur atom, an imino group, or a group shown by ##STR2## (wherein m represents 1 or 2 and R.sub.4 represents a lower alkyl group, a hydroxy lower alkyl group, a cycloalkyl group or a phenyl lower alkyl group); and Y represents an ethylene group which may be substituted by lower alkyl group, a trimethylene group, a tetramethylene group, a vinylene group which may be substituted by a lower alkyl group, or ##STR3## (wherein R.sub.5 represents a hydrogen atom, a lower alkyl group, a trifluoromethyl group, or a phenyl group); said X is the group shown by ##STR4## when one of said R.sub.1 and R.sub.2 is a lower alkyl group and the other is a hydrogen atom, and said Y is an ethylene group, and the pharmacologically acceptable non-toxic salts thereof. The compounds described above are strong analgesic anti-inflammatory agents.

  根据下面的公式所示的新型含氮杂环化合物，其中R.sub.1和R.sub.2中的一个代表低烷基基团、苯基、卤苯基或低烷氧基苯基，另一个代表氢原子、低烷基基团或苯低烷基基团；所述的R.sub.1和R.sub.2可以结合在一起形成三亚甲基基团或四亚甲基基团；R.sub.3代表氢原子、低烷基基团、苯基或苯低烷基基团；X代表氧原子、硫原子、亚胺基团或由##STR2##所示的基团（其中m代表1或2，R.sub.4代表低烷基基团、羟基低烷基基团、环烷基团或苯基低烷基基团）；Y代表乙烯基，可以被低烷基基团、三亚甲基基团、四亚甲基基团、乙烯基取代，或者##STR3##（其中R.sub.5代表氢原子、低烷基基团、三氟甲基基团或苯基）；当R.sub.1和R.sub.2中的一个是低烷基基团，另一个是氢原子时，X是由##STR4##所示的基团，Y是乙烯基，以及其药理学上可接受的无毒盐。上述描述的化合物是强效的镇痛抗炎药物。
• Novel fused derivatives of 2-pyridones
  申请人：Yamanouchi Pharmaceutical Co., Ltd.

  公开号：US04186200A1

  公开（公告）日：1980-01-29

  Novel nitrogen-containing heterocyclic compounds shown by the formula ##STR1## wherein one of R.sub.1 and R.sub.2 represents a lower alkyl group, a phenyl group, a halophenyl group, or a lower alkoxyphenyl group and the other of them represents a hydrogen atom, a lower alkyl group, or a phenyl lower alkyl group; said R.sub.1 and R.sub.2 may combine with each other to form a trimethylene group or a tetramethylene group; R.sub.3 represents a hydrogen atom, a lower alkyl group, a phenyl group, or a phenyl lower alkyl group; X represents an oxygen atom, a sulfur atom, an imino group, or a group shown by ##STR2## wherein m represents 1 or 2 and R.sub.4 represents a lower alkyl group, a hydroxy lower alkyl group, a cycloalkyl group or a phenyl lower alkyl group; and Y represents an ethylene group which may be substituted by lower alkyl group, a trimethylene group, a tetramethylene group, a vinylene group which may be substituted by a lower alkyl group, or ##STR3## wherein R.sub.5 represents a hydrogen atom, a lower alkyl group, a trifluoromethyl group, or a phenyl group; said X is the group shown by ##STR4## when one of said R.sub.1 and R.sub.2 is a lower alkyl group and the other is a hydrogen atom, and said Y is an ethylene group, and the pharmacologically acceptable non-toxic salts thereof. The compounds described above are strong analgesic anti-inflammatory agents.

  根据以下公式所示的新颖含氮杂环化合物：其中R.sub.1和R.sub.2中的一个代表较低的烷基基团、苯基、卤苯基团或较低的烷氧基苯基团，另一个代表氢原子、较低的烷基基团或苯较低的烷基基团；所述的R.sub.1和R.sub.2可以结合在一起形成三亚甲基基团或四亚甲基基团；R.sub.3代表氢原子、较低的烷基基团、苯基或苯较低的烷基基团；X代表氧原子、硫原子、亚胺基团或由##STR2##所示的基团，其中m代表1或2，R.sub.4代表较低的烷基基团、羟基较低的烷基基团、环烷基基团或苯较低的烷基基团；Y代表一个乙烯基，可以被较低的烷基基团取代，一个三亚甲基基团，一个四亚甲基基团，一个乙烯基可以被较低的烷基基团取代，或者##STR3##其中R.sub.5代表氢原子、较低的烷基基团、三氟甲基基团或苯基；当R.sub.1和R.sub.2中的一个是较低的烷基基团，另一个是氢原子时，X是由##STR4##所示的基团，Y是一个乙烯基，以及其药理学上可接受的无毒盐。上述化合物是强镇痛抗炎剂。
• Ligand-controlled E/Z selectivity and enantioselectivity in palladium-catalyzed allylation of benzofuranones with 1,2-disubstituted allylic carbonates
  作者：Kohsuke Ohmatsu、Mitsunori Ito、Takashi Ooi

  DOI：10.1039/c3cc49338e

  日期：——

  The first highly E- and enantioselective allylic alkylation of prochiral carbon nucleophiles with 1,2-disubstituted allylic carbonates is reported. The key is the ability of modular ion-paired chiral ligands to simultaneously control the E/Z selectivity and enantioselectivity.

  报道了一种高度E和对映选择性的烯丙基烷基化方法，使用1,2-二取代烯丙基碳酸酯与非手性碳亲核试剂反应。关键在于模块化离子对配体的能力，同时控制E/Z选择性和对映选择性。
• Regioselective catalytic addition of terminal acetylenes to methyl esters of 1-alkylcyclopropene-3-carboxylic acids
  作者：M. N. Protopopova、E. A. Shapiro、Yu. V. Tomilov、I. E. Dolgii、O. M. Nefedov

  DOI：10.1007/bf00963270

  日期：1985.10